

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/422,528	10/21/1999	WOON-LAM Susan LEUNG	P1190R1	5652
7590 12/18/2006 ATTN JANET E HASAK GENENTECH INC I DNA WAY SOUTH SAN FRANCISCO, CA 940804990			EXAMINER	
			FRONDA, CHRISTIAN L	
			ART UNIT	PAPER NUMBER
	,		1652	
	•			
			MAIL DATE	DELIVERY MODE
•			12/18/2006	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
09/422,528	LEUNG ET AL.	
Examiner	Art Unit	
Christian L. Fronda	1652	

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 05 September 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. 🛛 The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: a) The period for reply expires <u>6</u> months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL 2. The Notice of Appeal was filed on 05 September 2006. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). **AMENDMENTS** 3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below): (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: . (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 7. Tor purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1-25. Claim(s) withdrawn from consideration: ___ AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1), 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER 11.

The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet. 12. ☐ Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s). _____ 13. ☐ Other: .

Continuation of 11. does NOT place the application in condition for allowance because

The arguments filed 09/05/2006 have fully been considered. However, the examiner respectfully disagrees with applicants' position that there is no motivation to combine the references for reasons of record as supplemented below. The art of recombinant heterologous protein expression in bacterial host cells is well developed and widely used in biotechnology for obtaining a desired protein. The examiner maintains that elimination or reduction of contaminating biological materials including proteoglycan and polysaccharide components of the bacterial cell is important for the heterologous expression and purification of a desired protein.

The reference of Dennis et al. (WO 93/24633. Published 12/09/1993) cited in the IDS dated 06/19/2000 teaches a recombinant E.coli host cell comprising a plasmid containing a biosynthetic pathway coding for poly-b-hydroxybutyrate and a plasmid containing a lysozyme gene, and a process for the production an recovery of poly-b-hydroxybutyrate by culturing said recombinant E.coli host cell (see entire reference). The reference shows that lysozyme was important in the purification and recovery process of the product from the bacterial cell (see Examples 1-8). Thus, one of ordinary skill in the art ordinary skill in the art at the time the invention was made would be motivated to eliminate or reduce proteoglycan and polysaccharide components of the E.coli bacterial cell wall such that the E.coli host cell taught by Hart et al. is further transformed with the plasmid vector of Wetzel et al. Elimination or reduction of proteoglycan and polysaccharide components of the E.coli bacterial cell wall by action of the expressed lysozyme would enable a simpler purification of IGF-I or of any desired protein.

TEKCHAND SAIDHA